Human ROR1/dJ537F10.1/NTRKR1 ORF/cDNA clone-Adenovirus particle (NM_005012.4)

Cat. No.: vGMAD000585

Pre-made Human ROR1/dJ537F10.1/NTRKR1 Adenovirus for ROR1 overexpression in-vitro and in-vivo. The ROR1 adenoviral vector excels as a vehicle for transient gene transfection in both stable cell lines and primary cells, including DC cells, macrophages, cardiomyocytes, hepatocytes, and neurons. The purified ROR1-encoding adenovirus also stands out as a quintessential tool for in vivo studies and vaccine research initiatives.

At GM Vector Core (GMVC), we provide bespoke adenovirus development and manufacture various grades of adenoviruses utilizing cutting-edge techniques. Dive deeper into our offerings.

Target products collection

Go to ROR1/dJ537F10.1 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdf MSDS
pdf Datasheet

Product information

Catalog No. Product Name Adenovirus Grade Adenovirus quantity
vGMAD000585 Human ROR1 Adenovirus particle Research Grade-In vitro 1E+10PFU (1E+10pfu/ml×1ml)
5E+10PFU (1E+10pfu/ml×5ml)
1E+11PFU (1E+10pfu/ml×10ml)
Research Grade-In vivo 1E+11PFU (1E+11pfu/ml×1ml)
GMP-like Grade inquiry
GMP Grade inquiry


Product Description

Catalog ID vGMAD000585
Gene Name ROR1
Accession Number NM_005012.4
Gene ID 4919
Species Human
Product Type Adenovirus particle (overexpression)
Insert Length 2814 bp
Gene Alias dJ537F10.1,NTRKR1
Fluorescent Reporter GFP
Mammalian Cell Selection Null
Fusion Tag 3xflag (C-Terminal)
Promoter EF1
Resistance Kanamycin
ORF Nucleotide Sequence ATGCACCGGCCGCGCCGCCGCGGGACGCGCCCGCCGCTCCTGGCGCTGCTGGCCGCGCTGCTGCTGGCCGCACGCGGGGCTGCTGCCCAAGAAACAGAGCTGTCAGTCAGTGCTGAATTAGTGCCTACCTCATCATGGAACATCTCAAGTGAACTCAACAAAGATTCTTACCTGACCCTCGATGAACCAATGAATAACATCACCACGTCTCTGGGCCAGACAGCAGAACTGCACTGCAAAGTCTCTGGGAATCCACCTCCCACCATCCGCTGGTTCAAAAATGATGCTCCTGTGGTCCAGGAGCCCCGGAGGCTCTCCTTTCGGTCCACCATCTATGGCTCTCGGCTGCGGATTAGAAACCTCGACACCACAGACACAGGCTACTTCCAGTGCGTGGCAACAAACGGCAAGGAGGTGGTTTCTTCCACTGGAGTCTTGTTTGTCAAGTTTGGCCCCCCTCCCACTGCAAGTCCAGGATACTCAGATGAGTATGAAGAAGATGGATTCTGTCAGCCATACAGAGGGATTGCATGTGCAAGATTTATTGGCAACCGCACCGTCTATATGGAGTCTTTGCACATGCAAGGGGAAATAGAAAATCAGATCACAGCTGCCTTCACTATGATTGGCACTTCCAGTCACTTATCTGATAAGTGTTCTCAGTTCGCCATTCCTTCCCTGTGCCACTATGCCTTCCCGTACTGCGATGAAACTTCATCCGTCCCAAAGCCCCGTGACTTGTGTCGCGATGAATGTGAAATCCTGGAGAATGTCCTGTGTCAAACAGAGTACATTTTTGCAAGATCAAATCCCATGATTCTGATGAGGCTGAAACTGCCAAACTGTGAAGATCTCCCCCAGCCAGAGAGCCCAGAAGCTGCGAACTGTATCCGGATTGGAATTCCCATGGCAGATCCTATAAATAAAAATCACAAGTGTTATAACAGCACAGGTGTGGACTACCGGGGGACCGTCAGTGTGACCAAATCAGGGCGCCAGTGCCAGCCATGGAATTCCCAGTATCCCCACACACACACTTTCACCGCCCTTCGTTTCCCAGAGCTGAATGGAGGCCATTCCTACTGCCGCAACCCAGGGAATCAAAAGGAAGCTCCCTGGTGCTTCACCTTGGATGAAAACTTTAAGTCTGATCTGTGTGACATCCCAGCGTGCGATTCAAAGGATTCCAAGGAGAAGAATAAAATGGAAATCCTGTACATACTAGTGCCAAGTGTGGCCATTCCCCTGGCCATTGCTTTACTCTTCTTCTTCATTTGCGTCTGTCGGAATAACCAGAAGTCATCGTCGGCACCAGTCCAGAGGCAACCAAAACACGTCAGAGGTCAAAATGTAGAGATGTCAATGCTGAATGCATATAAACCCAAGAGCAAGGCTAAAGAGCTACCTCTTTCTGCTGTACGCTTTATGGAAGAATTGGGTGAGTGTGCCTTTGGAAAAATCTATAAAGGCCATCTCTATCTCCCAGGCATGGACCATGCTCAGCTGGTTGCTATCAAGACCTTGAAAGACTATAACAACCCCCAGCAATGGACGGAATTTCAACAAGAAGCCTCCCTAATGGCAGAACTGCACCACCCCAATATTGTCTGCCTTCTAGGTGCCGTCACTCAGGAACAACCTGTGTGCATGCTTTTTGAGTATATTAATCAGGGGGATCTCCATGAGTTCCTCATCATGAGATCCCCACACTCTGATGTTGGCTGCAGCAGTGATGAAGATGGGACTGTGAAATCCAGCCTGGACCACGGAGATTTTCTGCACATTGCAATTCAGATTGCAGCTGGCATGGAATACCTGTCTAGTCACTTCTTTGTCCACAAGGACCTTGCAGCTCGCAATATTTTAATCGGAGAGCAACTTCATGTAAAGATTTCAGACTTGGGGCTTTCCAGAGAAATTTACTCCGCTGATTACTACAGGGTCCAGAGTAAGTCCTTGCTGCCCATTCGCTGGATGCCCCCTGAAGCCATCATGTATGGCAAATTCTCTTCTGATTCAGATATCTGGTCCTTTGGGGTTGTCTTGTGGGAGATTTTCAGTTTTGGACTCCAGCCATATTATGGATTCAGTAACCAGGAAGTGATTGAGATGGTGAGAAAACGGCAGCTCTTACCATGCTCTGAAGACTGCCCACCCAGAATGTACAGCCTCATGACAGAGTGCTGGAATGAGATTCCTTCTAGGAGACCAAGATTTAAAGATATTCACGTCCGGCTTCGGTCCTGGGAGGGACTCTCAAGTCACACAAGCTCTACTACTCCTTCAGGGGGAAATGCCACCACACAGACAACCTCCCTCAGTGCCAGCCCAGTGAGTAATCTCAGTAACCCCAGATATCCTAATTACATGTTCCCGAGCCAGGGTATTACACCACAGGGCCAGATTGCTGGTTTCATTGGCCCGCCAATACCTCAGAACCAGCGATTCATTCCCATCAATGGATACCCAATACCTCCTGGATATGCAGCGTTTCCAGCTGCCCACTACCAGCCAACAGGTCCTCCCAGAGTGATTCAGCACTGCCCACCTCCCAAGAGTCGGTCCCCAAGCAGTGCCAGTGGGTCGACTAGCACTGGCCATGTGACTAGCTTGCCCTCATCAGGATCCAATCAGGAAGCAAATATTCCTTTACTACCACACATGTCAATTCCAAATCATCCTGGTGGAATGGGTATCACCGTTTTTGGCAACAAATCTCAAAAACCCTACAAAATTGACTCAAAGCAAGCATCTTTACTAGGAGACGCCAATATTCATGGACACACCGAATCTATGATTTCTGCAGAACTGTAA
ORF Protein Sequence MHRPRRRGTRPPLLALLAALLLAARGAAAQETELSVSAELVPTSSWNISSELNKDSYLTLDEPMNNITTSLGQTAELHCKVSGNPPPTIRWFKNDAPVVQEPRRLSFRSTIYGSRLRIRNLDTTDTGYFQCVATNGKEVVSSTGVLFVKFGPPPTASPGYSDEYEEDGFCQPYRGIACARFIGNRTVYMESLHMQGEIENQITAAFTMIGTSSHLSDKCSQFAIPSLCHYAFPYCDETSSVPKPRDLCRDECEILENVLCQTEYIFARSNPMILMRLKLPNCEDLPQPESPEAANCIRIGIPMADPINKNHKCYNSTGVDYRGTVSVTKSGRQCQPWNSQYPHTHTFTALRFPELNGGHSYCRNPGNQKEAPWCFTLDENFKSDLCDIPACDSKDSKEKNKMEILYILVPSVAIPLAIALLFFFICVCRNNQKSSSAPVQRQPKHVRGQNVEMSMLNAYKPKSKAKELPLSAVRFMEELGECAFGKIYKGHLYLPGMDHAQLVAIKTLKDYNNPQQWTEFQQEASLMAELHHPNIVCLLGAVTQEQPVCMLFEYINQGDLHEFLIMRSPHSDVGCSSDEDGTVKSSLDHGDFLHIAIQIAAGMEYLSSHFFVHKDLAARNILIGEQLHVKISDLGLSREIYSADYYRVQSKSLLPIRWMPPEAIMYGKFSSDSDIWSFGVVLWEIFSFGLQPYYGFSNQEVIEMVRKRQLLPCSEDCPPRMYSLMTECWNEIPSRRPRFKDIHVRLRSWEGLSSHTSSTTPSGGNATTQTTSLSASPVSNLSNPRYPNYMFPSQGITPQGQIAGFIGPPIPQNQRFIPINGYPIPPGYAAFPAAHYQPTGPPRVIQHCPPPKSRSPSSASGSTSTGHVTSLPSSGSNQEANIPLLPHMSIPNHPGGMGITVFGNKSQKPYKIDSKQASLLGDANIHGHTESMISAEL

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Biosimilar GMP-Bios-ab-647 Pre-Made Zilovertamab biosimilar, Whle mAb, Anti-ROR1 Antibody: Anti-NTRKR1/dJ537F10.1 therapeutic antibody
    Biosimilar GMP-Bios-INN-1057 Pre-Made Zilovertamab Vedotin Biosimilar, Whole Mab Adc, Anti-Ror1 Antibody: Anti-NTRKR1/dJ537F10.1 therapeutic antibody Drug Conjugate
    Target Antibody GM-Tg-g-T87871-Ab Anti-ROR1/ NTRKR1/ dJ537F10.1 monoclonal antibody
    Target Antigen GM-Tg-g-T87871-Ag ROR1 VLP (virus-like particle)
    ORF Viral Vector pGMLV000229 Human ROR1 Lentivirus plasmid
    ORF Viral Vector pGMAD000585 Human ROR1 Adenovirus plasmid
    ORF Viral Vector vGMLV000229 Human ROR1 Lentivirus particle
    ORF Viral Vector vGMAD000585 Human ROR1 Adenovirus particle


    Target information

    Target ID GM-T87871
    Target Name ROR1
    Gene ID 4919, 26563, 700760, 362550, 101100987, 489557, 783965, 100069962
    Gene Symbol and Synonyms 2810404D04Rik,dJ537F10.1,NTRKR1,RGD1559469,ROR1
    Uniprot Accession Q01973
    Uniprot Entry Name ROR1_HUMAN
    Protein Sub-location Transmembrane Protein
    Category Therapeutics Target, Immuno-oncology Target, INN Index
    Disease Not Available
    Gene Ensembl ENSG00000185483
    Target Classification Checkpoint-Immuno Oncology

    This gene encodes a receptor tyrosine kinase-like orphan receptor that modulates neurite growth in the central nervous system. The encoded protein is a glycosylated type I membrane protein that belongs to the ROR subfamily of cell surface receptors. It is a pseudokinase that lacks catalytic activity and may interact with the non-canonical Wnt signalling pathway. This gene is highly expressed during early embryonic development but expressed at very low levels in adult tissues. Increased expression of this gene is associated with B-cell chronic lymphocytic leukaemia. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jun 2012]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.